Reuters logo
BRIEF-Novo Nordisk VP says road is paved for timely US FDA approval of semaglutide
October 19, 2017 / 6:27 AM / in a month

BRIEF-Novo Nordisk VP says road is paved for timely US FDA approval of semaglutide

Oct 19 (Reuters) - NOVO NORDISK CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN SAID IN AN INTERVIEW:

* PANEL RECOMMENDATION OF SEMAGLUTIDE DRUG SHOULD PAVE WAY FOR TIMELY U.S. FDA APPROVAL

* U.S. FDA PANEL POINTS TO NEED FOR LARGER POST-APPROVAL STUDY FOR SEMAGLUTIDE

* STILL AN AMBITION TO INCLUDE CARDIOVASCULAR DATA FROM SUSTAIN6 TRAIL IN SEMAGLUTIDE LABEL Further company coverage: (Reporting by Jacob Gronholt-Pedersen)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below